To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL ® gene silencing technology to eliminate cancer. Phio today announced that podium presentations will be given on its two lead... Read More

Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3 rd Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in... Read More

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today... Read More

Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b... Read More

Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced... Read More

Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025.... Read More

Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced... Read More

Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio... Read More

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to be incurred in connection with PH-762 clinical activities Marlborough, Massachusetts--(Newsfile Corp. - January 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology... Read More

Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 610,000 shares of its... Read More

Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 833,335 shares of its... Read More

Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,063,670 shares of... Read More

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced... Read More

INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentation Marlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the publication... Read More

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 240,000 shares of its... Read More

Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 437,192 shares of its... Read More

Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company that develops therapeutics using its INTASYL ® siRNA gene silencing technology to make the body's immune cells more effective in killing... Read More

Journal is the official publication of the International Union of Immunological Societies Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. ( NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today its... Read More

Award is being presented during Advanced Therapies Week 2025 in Dallas Marlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced the company is a... Read More

Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio... Read More

Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its second patient cohort in its PH-762 Phase 1b dose-escalating clinical trial, and added a sixth clinical site in... Read More

Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells today reported its financial results for the quarter ended September 30, 2024 and provided... Read More

Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that... Read More

Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm EST Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer... Read More

New clinical data from Phio's on-going Phase 1b trial to be presented Marlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new clinical data from the on-going Phase 1b... Read More

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. ( NASDAQ: PHIO ), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual... Read More

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. ( NASDAQ: PHIO ), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual... Read More

PH-894: Potent and Specific Silencing of BRD4 in NK Cells Marlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it is... Read More

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is... Read More

Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 2, 2024) - Phio Pharmaceuticals Corp. ( NASDAQ: PHIO ), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual... Read More

Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its INTASYL compound PH-894 at the American Society of Gene & Cell Therapy's (ASGCT's) 2024 Advancing... Read More

Data will be presented at the conference in October in Montreal Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about INTASYL, its patented technology... Read More

Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - September 17, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) , a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual... Read More

Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is presenting data... Read More

Conference to be held in New York City September 9-11th Marlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp. ( NASDAQ: PHIO ), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that its President and CEO, Robert Bitterman, will be attending and... Read More

Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. ( NASDAQ: PHIO ), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual... Read More

Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2024 and provided a business update. Recent Corporate Updates The Phase 1b... Read More

Phio's INTASYL compound targets aging skin disorders Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that they have entered into an exploratory collaboration regarding opportunities... Read More

Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will... Read More

Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 545,286... Read More

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the addition of the University of Pittsburgh Medical Center (UPMC)... Read More

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the... Read More

Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL ® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of... Read More

Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown Marlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, has been granted a skin care patent in South Korea. The... Read More

Intratumoral PH-762 has encouraging safety profile in the initial cohort Escalation to proceed to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - May 28, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that a Safety... Read More

Phio to present a clinical study progress update on their lead clinical candidate, PH-762 Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its lead product... Read More

MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchase agreement with TRITON Funds. Subject to the terms of the purchase agreement, TRITON will purchase up to... Read More

MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its lead clinical candidate, PH-762, an INTASYL compound. The data is being presented in three posters at the annual... Read More

PH-762 is Phio’s lead product candidate Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced progress on its Phase 1b clinical study for their lead compound... Read More

Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1... Read More

MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead product candidate, PH-762, an INTASYL compound. PH-762 is currently being studied in a US clinical... Read More

Injection in murine tumors shows the compound is well tolerated Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells... Read More

MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical candidate, PH-762, an INTASYL compound. The data will be presented in three posters at the... Read More

MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound. Preclinical studies demonstrate that PH-762 is... Read More

Program will be airing on PBS with Dennis Quaid in April It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced its INTASYL platform will be the focus of... Read More

Four sites across the country participating in clinical trial for lead product candidate PH-762 Two patients have already completed treatment New patent granted for skin related treatments, extending Phio’s expertise in dermatological treatments for skin care and skin cancer MARLBOROUGH, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose... Read More

MARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about INTASYL on March 21 st . The event is scheduled to take place at the 10th Immunotherapy of Cancer Conference... Read More

MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the addition of three clinical trial sites for its Phase 1b study of PH-762: The George Washington University—Medical Faculty Associates in... Read More

MARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the United States Patent and Trademark Office (USPTO) has granted patent application 17/150,614 for two of its INTASYL Compounds, RXI-185... Read More

New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating the potential of INTASYL... Read More

MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common... Read More

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended September 30, 2023 and provided a business update. “We have enrolled the first patient in our U.S. clinical... Read More

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the first patient has been dosed in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that... Read More

MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the presentation of new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to take... Read More

MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating enhanced tumor control of the combination of an INTASYL compound targeting CTLA-4 and a systemic anti-PD-1... Read More

Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination Preclinical data demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent (directly killing tumor cells) Data to be presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 11 th -15 th MARLBOROUGH, Mass.,... Read More

MARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its President and CEO, Robert Bitterman, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11... Read More

MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its clinical development partners, AgonOx, Inc. and Providence Cancer Institute of Oregon, have dosed their first patient in an Adoptive Cell... Read More

MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2023 and provided a business update. “Following FDA clearance of our IND for PH-762, we are moving... Read More

MARLBOROUGH, Mass. , June 2, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the closing of its previously announced registered direct offering of 233,646 shares of common stock, at a purchase price of $4.28 per share. In a... Read More

MARLBOROUGH, Mass. , May 31, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 233,646 of its shares of common stock at a purchase price of... Read More

One of two newly announced clinical trials for its lead product candidate, PH-762 MARLBOROUGH, Mass. , May 24, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced its clinical development partner, AgonOx, Inc, in collaboration with... Read More

Data is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MARLBOROUGH, Mass. , May 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced pre-clinical data demonstrating that using INTASYL to... Read More

MARLBOROUGH, Mass. , May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to proceed with a clinical trial of... Read More

MARLBOROUGH, Mass. , May 11, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp . (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended March 31, 2023 and provided a business update. "Expecting to commence the Phase 1 clinical trial in adoptive... Read More

MARLBOROUGH, Mass. , April 20, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the closing of its previously announced registered direct offering of 353,983 shares of common stock, at a purchase price of $5.65 per share, priced... Read More

MARLBOROUGH, Mass. , April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 353,983 of its shares of common stock at a purchase price of... Read More

Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 MARLBOROUGH, Mass. , April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a mouse model of colon cancer... Read More

Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 MARLBOROUGH, Mass. , April 17, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a hepatocellular carcinoma model... Read More

Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma Received confirmation from the FDA that the planned Phase 1 clinical trial in patients with advanced solid tumors, in collaboration with Phio's development partner AgonOx, may proceed Newly integrated management and clinical teams continue to make significant... Read More

MARLBOROUGH, Mass. , Feb. 22, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that Robert Bitterman has been appointed by the Board of Directors to serve as the Company's President and Chief Executive Officer, effective as of... Read More

MARLBOROUGH, Mass. , Feb. 13, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing... Read More

MARLBOROUGH, Mass. , Feb. 10, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that an independent Data Monitoring Committee (DMC) completed its prespecified review of interim safety data in the Company's Phase 1b clinical trial of... Read More

MARLBOROUGH, Mass. , Jan. 25, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-12. The reverse stock split will... Read More

MARLBOROUGH, Mass. , Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its Principal Executive Officer and Executive Chairman, Robert Bitterman , will be a featured speaker at the Entrepreneurial Showcase at the Dermatology... Read More

MARLBOROUGH, Mass. , Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced their clinical development partner, AgonOx, Inc. has received confirmation from the FDA that their planned Phase 1 clinical trial in patients with advanced solid tumors may proceed. The initial Phase 1 clinical trial is designed to assess safety and to study the potential for an enhanced therapeutic benefit from the... Read More

MARLBOROUGH, Mass. , Dec. 21, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. , today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to... Read More